Laminin α2 chain-deficient congenital muscular dystrophy
Variable epitope expression in severe and mild cases
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To characterize the expression of distinct fragments of laminin α2 chain in patients with partial laminin α2 chain deficiency and variable clinical severity.
Background: Deficiency of laminin α2 chain caused by mutations of the LAMA2 gene on chromosome 6q2 account for approximately 50% of cases of congenital muscular dystrophy (CMD) in white patients. The complete absence of laminin α2 is usually associated with a severe phenotype affecting skeletal muscle and the peripheral and central nervous systems.
Methods: Quantitative assessment of immunofluorescence to study the expression of C- and N-terminal portions of laminin α2 chain in five patients with partial laminin α2 chain deficiency and variable phenotype. All five patients showed abnormal T2 signal on brain MRI.
Results: Immunohistochemistry of muscle specimens showed preserved or minimally reduced expression of the C-terminal region of the laminin α2 chain (67 to 74%), but a marked reduction of the N-terminal region in four patients (13 to 19%). One patient with a mild phenotype had a partial reduction (45%) of the C-terminal and the N-terminal (51%) portions of the laminin α2 chain. Two patients were unable to walk or sit, although the C-terminal portion of the laminin α2 chain was expressed at significant levels (67 to 74%). In contrast, two patients with a similar expression of the C-terminus (67 to 70%) had a milder phenotype and became ambulatory. It was impossible to predict the phenotypes in these four patients with a strong expression of the C-terminus and with low levels of the N-terminus based on the amount of protein expressed. In addition, the laminin β2 chain was moderately reduced (54 to 75%) in all patients with laminin α2 chain deficiency. A strong correlation between the amount of the C-terminus but not for the N-terminus and laminin β2 reduction could be observed.
Conclusions: N-terminal antibodies to the laminin α2 chain provide a more precise immunohistochemical detection of partially laminin α2 chain-deficient CMD. The secondary reduction of laminin β2 chain may better define laminin α2 chain-deficient CMD. More data are needed to predict which portions of C-terminus and midrod region of the laminin α2 chain result in a semifunctional protein and a milder phenotype.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Articles
Disruption of muscle basal lamina in congenital muscular dystrophy with merosin deficiencyC. Minetti, M. Bado, G. Morreale et al.Neurology, May 01, 1996 -
Brief Communications
Congenital muscular dystrophy with primary partial laminin α2 chain deficiency: Molecular studyY. He, K. J. Jones, N. Vignier et al.Neurology, October 09, 2001 -
Articles
Laminin α2 muscular dystrophyGenotype/phenotype studies of 22 patientsE. Pegoraro, H. Marks, C. A. Garcia et al.Neurology, July 01, 1998 -
Articles
A novel laminin α2 isoform in severe laminin α2 deficient congenital muscular dystrophyE. Pegoraro, M. Fanin, C.P. Trevisan et al.Neurology, October 24, 2000